<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01822587</url>
  </required_header>
  <id_info>
    <org_study_id>21392</org_study_id>
    <nct_id>NCT01822587</nct_id>
  </id_info>
  <brief_title>Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving</brief_title>
  <official_title>Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving, Reactivity and Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' recently completed study has provided the first evidence that
      administration of the medication propranolol, following exposure to cocaine cues, can alter
      drug-associated memories and reduce craving and other drug cue-elicited responses in cocaine
      addicted persons. The investigators will attempt to augment this effect by a) doubling the
      number of propranolol-medicated cocaine cue exposure (CCE) retrieval sessions and b)
      increasing the dose of propranolol. It is expected that propranolol treated groups, relative
      to placebo treated groups, will evidence greater reduction of craving, cue reactivity and
      cocaine use during follow-up cocaine cue exposures. Also, these effects will be greater for
      those who receive 80mg of propranolol as opposed to 40mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three groups of CD (cocaine dependant) participants will receive two sessions of cocaine cue
      exposure (CCE), each separated by a 24 hr. period and both conducted while the participants
      remain in hospital. One group (PBO) will receive placebo following each CCE session while the
      second (40PP) and third (80PP) group will receive 40 mg and 80 mg propranolol, respectively.
      Participants will return two days, and 1, 3, and 6 weeks after discharge and will be
      administered a CCE session to assess for maintenance/generalization of disruption of
      reconsolidation (DoR) effects on craving and cue reactivity to familiar and novel cocaine
      cues. Participants will also be assessed 3 times weekly for cocaine use (self-report &amp; urine
      drug screen) during follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">November 5, 2018</completion_date>
  <primary_completion_date type="Actual">November 5, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Use</measure>
    <time_frame>Evaluated at Weeks 1, 3 and 6</time_frame>
    <description>Timeline of cocaine use throughout the duration of the study (in dollar amounts)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Craving Score</measure>
    <time_frame>Single-Item Craving Scores are collected at all Retrieval Extinction Sessions (medication days), as well as all Phase Two Test Sessions (weeks 1,3 and 6).</time_frame>
    <description>The participant is asked, &quot;What is the level of craving you are experiencing on a scale or 0 to 100, with 0 representing no craving and 100 extreme craving&quot;?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Days of Abstinence</measure>
    <time_frame>Week 1, Week 3, and Week 6</time_frame>
    <description>How many days the participants used cocaine versus how many days of abstinence they were able to achieve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Peak Craving Score</measure>
    <time_frame>Day 2, Week 1, Week 3, and Week 6</time_frame>
    <description>Peak Craving Response from Session Baseline- peak craving is measured by a scale with a score of 0 (no craving) -100 (maximum craving).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Use Days</measure>
    <time_frame>Week 1, Week 3, Week 6</time_frame>
    <description>Mean Days of Cocaine Use</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Cocaine Addiction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered once orally following cue exposure on each of the first two days of testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administered once orally following cue exposure on each of the first two days of testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol, 80mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administered once orally following cue exposure on each of the first two days of testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol, 40 mg</intervention_name>
    <arm_group_label>Propranolol 40mg</arm_group_label>
    <other_name>Inderal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol, 80 mg</intervention_name>
    <arm_group_label>Propranolol, 80mg</arm_group_label>
    <other_name>Inderal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must meet DSM-IV criteria for current cocaine dependence (within the past
             month). Participants may meet criteria for abuse, but not dependence, for any other
             substance with the exception of nicotine. Because of the high comorbidity of cocaine
             and nicotine dependence, excluding nicotine dependence would seriously compromise the
             feasibility of recruitment (nicotine patch will be provided to participants during the
             course of their involvement in the laboratory procedures). Although individuals who
             meet criteria for alcohol abuse will be accepted for study participation, anyone who
             has a measurable blood alcohol level on the day of testing will be excluded as acute
             alcohol intake can lower seizure threshold.

          -  Participants must be able to provide informed consent and function at an intellectual
             level sufficient to allow accurate completion of all assessment instruments.Exclusion
             Criteria:

          -  Use of one of the following methods of birth control by female participants: barrier
             methods (diaphragm or condoms with spermicidal or both), surgical sterilization, use
             of an intra-uterine contraceptive device, or complete abstinence from sexual
             intercourse.

          -  Individuals must live within a 50-mile radius of our research program and have
             reliable transportation.

          -  Individuals must consent to remain abstinent from all drugs of abuse (except nicotine)
             for 72 hours immediately prior to CTRC inpatient admission.

          -  Individuals must consent to random assignment to one of three study groups (the two
             propranolol-treated groups or the placebo-treated group).

        Exclusion Criteria:

          -  Women who are pregnant, nursing or of childbearing potential and not practicing an
             effective means of birth control.

          -  Individuals with evidence of or a history of significant hematological, endocrine,
             cardiovascular, pulmonary, renal, gastrointestinal, or neurological disease including
             diabetes, as these conditions may affect heart rate or skin conductance measurement.

          -  Individuals with significant liver impairment as propranolol is hepatically
             metabolized.

          -  Individuals with a history of or current psychotic disorder, current major depressive
             disorder, bipolar affective disorder or a severe anxiety disorder as these may impact
             cue reactivity.

          -  Individuals currently taking anti-arrythmic agents, psychostimulants or any other
             agents known to interfere with heart rate and skin conductance monitoring.

          -  Known or suspected hypersensitivity to propranolol.

          -  Individuals taking medications that could adversely interact with the study
             medication, including, but not limited to albuterol, insulin, or significant
             inhibitors of CYP2D6.

          -  Individuals with bronchial asthma or chronic obstructive pulmonary disease, as the use
             of propranolol is contraindicated in these individuals.

          -  Individuals with any physical condition or disability that would compromise optimal
             sensory processing of the cues (e.g., blindness).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael E Saladin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>April 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2013</study_first_posted>
  <results_first_submitted>November 4, 2019</results_first_submitted>
  <results_first_submitted_qc>November 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2019</results_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Abuse</keyword>
  <keyword>Cocaine</keyword>
  <keyword>Addiction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT01822587/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Administered once orally following cue exposure on each of the first two days of testing.
Placebo</description>
        </group>
        <group group_id="P2">
          <title>Propranolol 40mg</title>
          <description>Administered once orally following cue exposure on each of the first two days of testing.
Propranolol, 40 mg</description>
        </group>
        <group group_id="P3">
          <title>Propranolol, 80mg</title>
          <description>Administered once orally following cue exposure on each of the first two days of testing.
Propranolol, 80 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Administered once orally following cue exposure on each of the first two days of testing.
Placebo</description>
        </group>
        <group group_id="B2">
          <title>Propranolol 40mg</title>
          <description>Administered once orally following cue exposure on each of the first two days of testing.
Propranolol, 40 mg</description>
        </group>
        <group group_id="B3">
          <title>Propranolol, 80mg</title>
          <description>Administered once orally following cue exposure on each of the first two days of testing.
Propranolol, 80 mg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="62"/>
            <count group_id="B4" value="181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.8" lower_limit="21" upper_limit="69"/>
                    <measurement group_id="B2" value="43.8" lower_limit="21" upper_limit="65"/>
                    <measurement group_id="B3" value="42.3" lower_limit="19" upper_limit="59"/>
                    <measurement group_id="B4" value="43.6" lower_limit="19" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed/Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Use</title>
        <description>Timeline of cocaine use throughout the duration of the study (in dollar amounts)</description>
        <time_frame>Evaluated at Weeks 1, 3 and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Administered once orally following cue exposure on each of the first two days of testing.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Propranolol 40mg</title>
            <description>Administered once orally following cue exposure on each of the first two days of testing.
Propranolol, 40 mg</description>
          </group>
          <group group_id="O3">
            <title>Propranolol, 80mg</title>
            <description>Administered once orally following cue exposure on each of the first two days of testing.
Propranolol, 80 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Use</title>
          <description>Timeline of cocaine use throughout the duration of the study (in dollar amounts)</description>
          <units>Dollar amounts of cocaine use</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9" spread="31.95"/>
                    <measurement group_id="O2" value="71.57" spread="31.63"/>
                    <measurement group_id="O3" value="69.63" spread="30.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.25" spread="32.67"/>
                    <measurement group_id="O2" value="177.67" spread="32.34"/>
                    <measurement group_id="O3" value="135.81" spread="31.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186.57" spread="33.21"/>
                    <measurement group_id="O2" value="198.9" spread="32.85"/>
                    <measurement group_id="O3" value="242.79" spread="32.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Craving Score</title>
        <description>The participant is asked, &quot;What is the level of craving you are experiencing on a scale or 0 to 100, with 0 representing no craving and 100 extreme craving&quot;?</description>
        <time_frame>Single-Item Craving Scores are collected at all Retrieval Extinction Sessions (medication days), as well as all Phase Two Test Sessions (weeks 1,3 and 6).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Administered once orally following cue exposure on each of the first two days of testing.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Propranolol 40mg</title>
            <description>Administered once orally following cue exposure on each of the first two days of testing.
Propranolol, 40 mg</description>
          </group>
          <group group_id="O3">
            <title>Propranolol, 80mg</title>
            <description>Administered once orally following cue exposure on each of the first two days of testing.
Propranolol, 80 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Craving Score</title>
          <description>The participant is asked, &quot;What is the level of craving you are experiencing on a scale or 0 to 100, with 0 representing no craving and 100 extreme craving&quot;?</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" spread="3.0"/>
                    <measurement group_id="O2" value="31.4" spread="2.9"/>
                    <measurement group_id="O3" value="26.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="2.8"/>
                    <measurement group_id="O2" value="28.0" spread="2.8"/>
                    <measurement group_id="O3" value="24.7" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" spread="2.9"/>
                    <measurement group_id="O2" value="29.0" spread="2.9"/>
                    <measurement group_id="O3" value="20.0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="2.8"/>
                    <measurement group_id="O2" value="22.4" spread="2.7"/>
                    <measurement group_id="O3" value="17.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Days of Abstinence</title>
        <description>How many days the participants used cocaine versus how many days of abstinence they were able to achieve.</description>
        <time_frame>Week 1, Week 3, and Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Administered once orally following cue exposure on each of the first two days of testing.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Propranolol 40mg</title>
            <description>Administered once orally following cue exposure on each of the first two days of testing.
Propranolol, 40 mg</description>
          </group>
          <group group_id="O3">
            <title>Propranolol, 80mg</title>
            <description>Administered once orally following cue exposure on each of the first two days of testing.
Propranolol, 80 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Days of Abstinence</title>
          <description>How many days the participants used cocaine versus how many days of abstinence they were able to achieve.</description>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Peak Craving Score</title>
        <description>Peak Craving Response from Session Baseline- peak craving is measured by a scale with a score of 0 (no craving) -100 (maximum craving).</description>
        <time_frame>Day 2, Week 1, Week 3, and Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Administered once orally following cue exposure on each of the first two days of testing.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Propranolol 40mg</title>
            <description>Administered once orally following cue exposure on each of the first two days of testing.
Propranolol, 40 mg</description>
          </group>
          <group group_id="O3">
            <title>Propranolol, 80mg</title>
            <description>Administered once orally following cue exposure on each of the first two days of testing.
Propranolol, 80 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Average Peak Craving Score</title>
          <description>Peak Craving Response from Session Baseline- peak craving is measured by a scale with a score of 0 (no craving) -100 (maximum craving).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="3.5"/>
                    <measurement group_id="O2" value="23.3" spread="3.4"/>
                    <measurement group_id="O3" value="18.1" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="3.5"/>
                    <measurement group_id="O2" value="19.6" spread="3.5"/>
                    <measurement group_id="O3" value="17.1" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="3.6"/>
                    <measurement group_id="O2" value="19.7" spread="3.6"/>
                    <measurement group_id="O3" value="10.1" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="3.6"/>
                    <measurement group_id="O2" value="12.1" spread="3.6"/>
                    <measurement group_id="O3" value="5.5" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Use Days</title>
        <description>Mean Days of Cocaine Use</description>
        <time_frame>Week 1, Week 3, Week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Administered once orally following cue exposure on each of the first two days of testing.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Propranolol 40mg</title>
            <description>Administered once orally following cue exposure on each of the first two days of testing.
Propranolol, 40 mg</description>
          </group>
          <group group_id="O3">
            <title>Propranolol, 80mg</title>
            <description>Administered once orally following cue exposure on each of the first two days of testing.
Propranolol, 80 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Use Days</title>
          <description>Mean Days of Cocaine Use</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="0.54"/>
                    <measurement group_id="O2" value="1.61" spread="0.53"/>
                    <measurement group_id="O3" value="1.76" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" spread="0.55"/>
                    <measurement group_id="O2" value="3.15" spread="0.54"/>
                    <measurement group_id="O3" value="3.51" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="0.56"/>
                    <measurement group_id="O2" value="4.49" spread="0.55"/>
                    <measurement group_id="O3" value="6.06" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events will be monitored throughout the study (six weeks) and all events will be followed to resolution or stabilization.</time_frame>
      <desc>A serious adverse event is one that meets any of the following criteria:
Fatal or life threatening
Requires or prolongs inpatient hospitalization
Results in persistent or significant disability/incapacity
Congenital anomaly
Medical event that may jeopardize the participant or require intervention to mitigate serious outcome
Cancer
Overdose</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Administered once orally following cue exposure on each of the first two days of testing.
Placebo</description>
        </group>
        <group group_id="E2">
          <title>Propranolol 40mg</title>
          <description>Administered once orally following cue exposure on each of the first two days of testing.
Propranolol, 40 mg</description>
        </group>
        <group group_id="E3">
          <title>Propranolol, 80mg</title>
          <description>Administered once orally following cue exposure on each of the first two days of testing.
Propranolol, 80 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Participant Hospitalization</sub_title>
                <description>Participant was hospitalized for depression and suicidal thoughts (no attempt).</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Saladin</name_or_title>
      <organization>MUSC</organization>
      <phone>843-792-5306</phone>
      <email>saladinm@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

